Evaluate the impact of 18F-FDG-PET-CT on the staging of patients with muscle invasive bladder cancer. Based on the results of 2 18F-FDG-PET-CT's patients are stratified in non-metastatic, oligometastatic and polymetastatic bladder cancer patients and the treatment is adapted accordingly to improve overall survival.
Histopathology-proven MIBC on TURb or ≥ T3 on conventional imaging treated with MIBC radical treatment
T1-4 N0-3 M0 MIBC on conventional imaging (thoracic CT and abdominopelvic CT/ MRI)
Age > 18 years
WHO 0-2
Presence of distant metastasis on conventional imaging (thoracic CT and abdominopelvic CT/ MRI)
Refusal of or having contraindications to 18F-FDG-PET-CT
Refusal of MDT or immunotherapy
Prior radiotherapy unabling MDT
University Hospital, Ghent
Lead sponsor
Kom Op Tegen Kanker
Collaborator